2016 American Society of Clinical Oncology Annual Meeting*

June 3-7, 2016; Chicago, Illinois
This program provides coverage of the 2016 ASCO annual meeting with PowerPoint summaries and expert analysis of the most clinically relevant study results with downloadable highlights slidesets. Topics include multiple solid tumors and hematologic malignancies.
John M. Burke, MD
David R. Gandara, MD
Daniel M. Geynisman, MD
Sara Hurvitz, MD, FACP
Elias Jabbour, MD
Rami S. Komrokji, MD
Shaji Kumar, MD
Brian Rini, MD, FACP
Tiffany A. Traina, MD
person default
Heather Wakelee, MD
Heather Wakelee, MD

Breast Cancer

Treatment with TaxAC superior to TC in pooled analysis of women with resected high-risk HER2-negative early breast cancer.

Released: June 7, 2016

With 5-year follow-up, local surgery followed by systemic therapy associated with significant improvement in OS vs initial systemic therapy with local therapy for localized progression in patients with MBC at presentation.

Released: June 6, 2016

Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.

Released: June 7, 2016

Phase III investigation of neoadjuvant T-DM1 plus pertuzumab showed a favorable safety profile but lower clinical response rate compared with chemotherapy with trastuzumab plus pertuzumab in HER2-positive early breast cancer.

Released: June 6, 2016

Addition of pertuzumab to trastuzumab and capecitabine improved median OS by 8 months in patients with HER2-positive metastatic breast cancer who previously progressed during/after trastuzumab-based therapy but did not meet the primary endpoint of the study.

Released: June 9, 2016

Palbociclib + letrozole achieved longest improvement in PFS seen to date for frontline treatment of ER+/HER2- advanced breast cancer.

Released: June 14, 2016

Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals.

Released: June 6, 2016

Here are the breast cancer abstracts that I am most interested in hearing about at this year’s ASCO annual meeting.

Sara Hurvitz, MD, FACP Released: May 31, 2016

Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, provide their expert analysis of key breast cancer presentations from the 2016 ASCO Annual Meeting in Chicago.

Sara Hurvitz, MD, FACP Tiffany A. Traina, MD Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: August 24, 2016 Expiration: August 23, 2017

This study conducted by the Canadian Cancer Trials Group is the first to show that extending aromatase inhibitor therapy beyond 5 years reduces the risk of disease recurrence.

Released: June 7, 2016

In this downloadable slideset, Sara Hurvitz, MD, FACP, and Tiffany A. Traina, MD, review important presentations in breast cancer from the 2016 ASCO meeting in Chicago.

Released: August 16, 2016

Genitourinary Cancers

PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.

Released: June 14, 2016

Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.

Released: June 9, 2016

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.

Released: June 6, 2016

Patient-reported outcomes from CHAARTED indicate that adding docetaxel to ADT increased physical symptoms during first 3 months of treatment but was associated with significantly improved QoL at 12 mos in patients with mHSPC.

Released: June 7, 2016

Cabazitaxel and docetaxel show similar clinical activity in mCRPC but with distinct safety profiles.

Released: June 7, 2016

Results from this small exploratory study suggest that radium-223 retreatment is well tolerated and may help delay future bone events in patients with CRPC and bone metastases who experience radiographic or clinical progression following an initial course of radium-223.

Released: June 7, 2016

Here are my thoughts on the abstracts from ASCO 2016 that have the most potential to change clinical practice.

Brian Rini, MD, FACP Released: May 31, 2016

In this activity, Daniel M. Geynisman, MD, and Brian Rini, MD, FACP, analyze and discuss the most clinically relevant data on the management of genitourinary cancers presented at the 2016 ASCO annual meeting.

Daniel M. Geynisman, MD Brian Rini, MD, FACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 12, 2016 Expiration: August 11, 2017

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.

Released: June 6, 2016

In this downloadable slideset, Daniel M. Geynisman, MD and Brian Rini, MD, review key data presented at the 2016 annual meeting of the American Society of Clinical Oncology.

Released: August 12, 2016

Hematologic Malignancies

Randomized phase III investigation of CPX-351 vs “7 + 3” induction identified a potential new standard of care for older patients with previously untreated high-risk AML.

Released: June 8, 2016

Fractionated dosing of CTL019 minimized CRS-related toxicity and maintained high response rates in patients with relapsed/refractory CD19+ ALL.

Released: June 6, 2016

Preinfusion disease burden associated with increased rates of cytokine release syndrome after 19-28z CAR-modified T-cell therapy.

Released: June 6, 2016

Early-phase study suggests promise of venetoclax plus low-dose cytarabine in untreated elderly patients with acute myeloid leukemia.

Released: June 6, 2016

Long-term analysis shows durable reductions in splenomegaly and significantly prolonged survival with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.

Released: June 7, 2016

This propensity score analysis comparing 2 phase II studies shows improved EFS and OS with addition of ponatinib vs dasatinib to standard HCVAD chemotherapy in newly diagnosed Ph+ ALL.

Released: June 13, 2016

Mogamulizumab produces clinical response in a population of adult patients with relapsed/refractory ATL who currently have no consensus treatment options.

Released: June 7, 2016

Early investigation of lenalidomide in a patient population with a poor prognosis demonstrates tolerability with some durable responses.

Released: June 14, 2016

Phase II data demonstrate that venetoclax monotherapy is active in patients with R/R CLL and prior treatment with either ibrutinib or idelalisib, including those with refractory disease.

Released: June 6, 2016

Early investigation of the next-generation BTK inhibitor acalabrutinib suggests that this agent can be used safely and has promising activity in previously untreated CLL patients, with no disease progression observed at a median follow-up of 10.5 months.

Released: June 8, 2016

Study confirmed a continued role for upfront ASCT in fit patients with newly diagnosed MM.

Released: June 7, 2016

A meta-analysis of 3 phase III trials shows lenalidomide maintenance after ASCT significantly increased OS by an estimated 2.5 yrs vs placebo or no maintenance in patients with newly diagnosed multiple myeloma.

Released: June 6, 2016

Early-phase data from a single-arm study demonstrate favorable safety and efficacy for the KPd combination in a population of patients with relapsed/refractory MM who were largely refractory to lenalidomide.

Released: June 6, 2016

Early-phase study of pembrolizumab plus lenalidomide plus dexamethasone in heavily pretreated MM showed 50% ORR, including a 38% rate in lenalidomide-refractory patients.

Released: June 8, 2016

Early study of venetoclax in combination with bortezomib/dexamethasone yields ORR in more than 80% of patients with R/R MM not refractory to bortezomib.

Released: June 9, 2016

The current modeling analysis shows that the addition of carfilzomib to lenalidomide/dexamethasone provides an additional 1.99 LYs and 1.67 QALYs vs lenalidomide/dexamethasone, as well as providing an ICER that ranges between $74,000 and $109,000.

Released: June 10, 2016

Addition of carfilzomib to lenalidomide/low-dose dexamethasone improved PFS and ORR in patients with MM who relapsed within 1 year after first previous therapy or transplantation.

Released: June 14, 2016

Here are expert thoughts on the hematologic malignancies abstracts from ASCO 2016 that have the most potential to change clinical practice.

Shaji Kumar, MD Released: May 31, 2016

John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, provide an analysis of key presentations on hematologic malignancies from the 2016 clinical oncology meeting in Chicago.

John M. Burke, MD Elias Jabbour, MD Rami S. Komrokji, MD Shaji Kumar, MD Physicians: maximum of 2.5 AMA PRA Category 1 Credits Released: September 8, 2016 Expiration: September 7, 2017

The investigators of this randomized phase III trial suggest that adding daratumumab to bortezomib/dexamethasone should be considered as a new standard of care for patients with relapsed/refractory multiple myeloma.

Released: June 8, 2016

John M. Burke, MD; Elias Jabbour, MD; Rami S. Komrokji, MD; and Shaji Kumar, MD, provide an analysis of key presentations on hematologic malignancies from the 2016 clinical oncology meeting in Chicago.

Released: August 30, 2016

Lung Cancer

Crizotinib shows antitumor activity, with a tolerable safety profile, in NSCLC with MET exon 14 alterations.

Released: June 7, 2016

Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.

Released: June 6, 2016

Concurrent CRT using modern RT techniques produced similar rates of survival and toxicity whether given once daily or twice daily for limited-stage SCLC.

Released: June 7, 2016

DFS and OS outcomes similar in patients with early-stage, resected NSCLC for 4 different cisplatin-based doublet chemotherapy regimens tested.

Released: June 8, 2016

Early phase data suggest that osimertinib is safe, tolerable, and produces clinical benefit in patients with difficult-to-treat NSCLC.

Released: June 10, 2016

In oligometastatic NSCLC without progression after first-line systemic therapy, local consolidative therapy significantly improved PFS without increasing toxicity.

Released: June 9, 2016

Brigatinib showed a 54% ORR with a median PFS > 1 year in patients with crizotinib-refractory ALK+ NSCLC.

Released: June 13, 2016

J-ALEX met its primary endpoint--alectinib significantly improved PFS vs crizotinib with a favorable safety profile in ALK inhibitor–naive patients with ALK-positive NSCLC.

Released: June 10, 2016

Lorlatinib is well tolerated in ALK+ and ROS1+ NSCLC and shows antitumor activity, including intracranial activity, in patients pretreated with available inhibitors of ALK and ROS1.

Released: June 7, 2016

Treatment-experienced patients with rare RET-fusion driver mutations responded well to single-agent vandetanib in this small trial, with more than one half of patients achieving an objective response.

Released: June 6, 2016

Here are the studies being presented at ASCO 2016 that David R. Gandara, MD, and I think are most likely to affect clinical practice in our patients with lung cancer.

David R. Gandara, MD person default Heather Wakelee, MD Released: May 31, 2016

David R. Gandara, MD, and Heather A. Wakelee, MD, review and analyze important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.

David R. Gandara, MD Heather Wakelee, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 18, 2016 Expiration: August 17, 2017

In this phase I study, the antibody–drug conjugate rovalpituzumab tesirine demonstrated good response rates in patients with relapsed/refractory SCLC and high DLL3 expression, making it the first biomarker-directed therapy with activity in this disease.

Released: June 7, 2016

In this downloadable slideset, David R. Gandara, MD, and Heather A. Wakelee, MD, review important lung cancer presentations from the 2016 clinical oncology meeting in Chicago.

Released: August 17, 2016

Immunotherapy

Phase Ib trial of combination therapy with atezolizumab and nab-paclitaxel showed a safety profile similar to each agent alone and produced durable responses in patients with mTNBC.

Released: June 7, 2016

Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.

Released: June 9, 2016

PD-L1 expression, TCGA subtype, and mutational load were independent predictors of atezolizumab response in patients with mUC, and response prediction improved significantly with combination of these markers.

Released: June 14, 2016

Evaluation of patients with metastatic NSCLC treated past first RECIST defined progression with anti–PD-1 therapy in clinical trials finds that a small proportion (8%) attained a subsequent response to treatment.

Released: June 6, 2016

Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.

Released: June 14, 2016

MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.

Released: June 10, 2016

Nivolumab treatment beyond progression associated with reduced tumor burden, improved OS, and lower incidence of all grade adverse events in patients with advanced RCC.

Released: June 9, 2016

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in heavily pretreated patients with metastatic urothelial carcinoma.

Released: June 6, 2016

Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.

Released: June 9, 2016

Fractionated dosing of CTL019 minimized CRS-related toxicity and maintained high response rates in patients with relapsed/refractory CD19+ ALL.

Released: June 6, 2016

Early-phase study of pembrolizumab plus lenalidomide plus dexamethasone in heavily pretreated MM showed 50% ORR, including a 38% rate in lenalidomide-refractory patients.

Released: June 8, 2016

Median OS not reached for pembrolizumab at median follow-up of 23 months, with continuing durable responses and favorable safety profile.

Released: June 13, 2016

Pembrolizumab plus ipilimumab appear to be well tolerated and produced robust, durable responses in patients with advanced melanoma.

Released: June 14, 2016

Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.

Released: June 6, 2016

David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, each provide an analysis of key presentations on cancer immunotherapy from the 2016 clinical oncology meeting in Chicago.

David R. Gandara, MD Daniel M. Geynisman, MD Sara Hurvitz, MD, FACP Elias Jabbour, MD Shaji Kumar, MD Brian Rini, MD, FACP Tiffany A. Traina, MD Heather Wakelee, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 23, 2016 Expiration: September 22, 2017

Atezolizumab shows rapid and durable clinical responses and a tolerable safety profile in previously untreated, cisplatin-ineligible patients with advanced or metastatic urothelial carcinoma.

Released: June 6, 2016

David R. Gandara, MD; Daniel M. Geynisman, MD; Sara Hurvitz, MD, FACP; Elias Jabbour, MD; Shaji Kumar, MD; Brian Rini, MD, FACP; Tiffany A. Traina, MD; and Heather A. Wakelee, MD, provide an analysis of key presentations on cancer immunotherapy from the 2016 Clinical Oncology meeting in Chicago.

Released: September 19, 2016

Gynecologic Cancers

5-year follow-up of Study 19 to determine if olaparib maintenance monotherapy maintained a survival advantage over placebo in patients with BRCA-mutated platinum-sensitive ovarian cancer.

Released: June 8, 2016

Phase Ib trial of pembrolizumab in PD-L1–positive advanced cervical cancer showed promising 6-month OS of 67% and safety profile similar to that seen in other tumor types.

Released: June 9, 2016

Prior bevacizumab did not adversely affect efficacy or safety of subsequent bevacizumab retreatment in recurrent platinum-sensitive ovarian cancer.

Released: June 6, 2016

IP carboplatin shows substantial reduction in PD rates at 9 months vs IV chemotherapy with similar tolerability.

Released: June 9, 2016

Gastrointestinal Cancers

Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.

Released: June 9, 2016

Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.

Released: June 14, 2016

MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.

Released: June 10, 2016

Tumor location appears to be prognostic of PFS, OS, and predictive of response to biologic agents in KRAS wt mCRC.

Released: June 8, 2016

Subanalysis of phase III RECOURSE trial suggests clinical benefit of TAS-102 in specific patients with metastatic CRC.

Released: June 13, 2016

Survival benefit was consistent across prognostic criteria of grade, disease stage, lymph node involvement, and resection margins, and there was no significant difference in treatment-related serious adverse events between the 2 treatment arms.

Released: June 14, 2016

Skin Cancers

Binimetinib significantly improved PFS and response rates in NRAS-mutant melanoma, particularly in patients who received prior immunotherapy.

Released: June 10, 2016

Median OS not reached for pembrolizumab at median follow-up of 23 months, with continuing durable responses and favorable safety profile.

Released: June 13, 2016

Pembrolizumab plus ipilimumab appear to be well tolerated and produced robust, durable responses in patients with advanced melanoma.

Released: June 14, 2016

Small phase Ib trial demonstrated that combination treatment with T-VEC plus pembrolizumab in advanced unresectable melanoma yields ORR of 57% and CR of 24%.

Released: June 6, 2016
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC in collaboration with Postgraduate Institute for Medicine
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
Amgen
Ariad Pharmaceuticals
Bayer Healthcare Pharmaceuticals Inc.
Celgene Corporation
Genentech
Incyte
Merck & Co., Inc.
Taiho Pharmaceuticals

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?